RxDoctor Payments DataLook up a doctor →

Saurabh Lalan, MD

Neurology · Lawton, OKNPI 1679833917

Payments from drug & device makers

$14,689in general payments, 2019–2025

Across 485 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$3K
  • AbbVie$2K
  • EMD Serono, Inc.$979
  • Teva Pharmaceuticals USA, Inc.$924
  • UCB, Inc.$817
  • Medtronic$683
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$2,45017%
  • Speaking & faculty fees$330%
  • Travel & lodging$4903%
  • Food & beverage$11,29077%
  • Education$4273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,689 in reported general payments places this provider in the 70th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$60,653
Medicare patients
250
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$117,317
NayzilamMidazolam60$48,583
EliquisApixaban59$29,607
Nurtec OdtRimegepant Sulfate24$24,327
UbrelvyUbrogepant22$23,607
XcopriCenobamate22$23,237
Ajovy AutoinjectorFremanezumab-Vfrm26$23,171
Aimovig AutoinjectorErenumab-Aooe21$19,005
ValtocoDiazepam11$16,713
BriviactBrivaracetam14$14,960
Emgality PenGalcanezumab-Gnlm21$14,814
Ajovy SyringeFremanezumab-Vfrm12$8,584
RytaryCarbidopa/Levodopa12$6,001
Lacosamide65$2,291
Felbamate13$2,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$452$117,31714 claims
UCB, Inc.Nayzilam, Briviact$817$63,54474 claims
PfizerEliquis, Nurtec Odt$86$53,93483 claims
AbbVieUbrelvy$2,139$23,60722 claims
SK Life Science, Inc.Xcopri$3,146$23,23722 claims
Neurelis, Inc.Valtoco$573$16,71311 claims
Amneal Pharmaceuticals LLCRytary$159$6,00112 claims
Upsher-smith Laboratories LLCTopiramate$29$87386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 152 neurology providers in Oklahoma.

Other neurology in Lawton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →